- Tags: retina
Research
Study: High-intensity exercise critical for reducing DR
Physical activity also improved peripheral retinal vessel measurements, with benefits peaking around five sessions and 180 minutes per week.
Business
Biogen is purchasing Apellis
With an estimated price tag of $5.6 billion, the acquisition includes the FDA-approved SYFOVRE.
Research
Vascular changes emerge in later MacTel stages
Study findings suggest retinal vascular alterations become more pronounced in advanced disease stages.
Pipeline
FDA grants Orphan Drug Designation to SignaBlok's ROP therapy
TREM-1 inhibitor is designed to selectively target inflammation via a noninvasive delivery; company plans to report preclinical data at ARVO annual meeting.
Research
Could TKI use cause RVO development?
Tyrosine kinase inhibitors may act as an additional risk factor for RVO in patients with existing vascular comorbidities.
Business
Cencora to buy EyeSouth Partners' retina division in $1B deal
Deal will integrate the MCO’s retina business into Retina Consultants of America, expanding its nationwide network of affiliate retina practices.
Products
Eyedaptic launches latest version of AI-based smart glasses for AMD
Designed for patients with retinal diseases, the EYE7 is an integrated wearable solution with real-time vision enhancements and a new visual assistant.
Research
Study urges alternative tracking for wet AMD poor responders
Structural change tracking indicates subretinal fibrosis may drive vision loss, calling for a shift in patient monitoring.
Events
AAOptometry to hold regional Retina Summit in Indianapolis
First-ever regional meeting kicks off on April 18 with 6.5 hours of CE featuring education sessions on the latest in retinal diagnosis and management.
Pipeline
EyePoint begins dosing in phase 3 DME trials for DURAVYU
COMO and CAPRI pivotal studies are evaluating vorolanib insert when intravitreally-injected every 6 months; topline data expected H2 2027.
Business
iCare and MediWhale partner on AI-based CVD retinal imaging
Strategic collaboration would integrate iCare’s DRSplus fundus imaging system with the autonomous Mr. Noon CVD software to predict patients’ CVD risk.
Research
Seasonal variations play major role in CSC development
Observed increased incidence of CSC in spring and autumn provide potential insights into the disease’s pathogenesis.
Research
Reducing chronic inflammation minimizes AMD-linked vision loss
Mouse model demonstrates role of NLRP3 in AMD pathology and highlights potential therapeutic approaches.
Research
Researchers develop clinical decision tool for GA treatment
Atrophy Advisor could help clinicians determine the optimal therapeutic approach for GA patients.
Research
First real-world data shows early promise of high-dose aflibercept for wet AMD
Eight-week findings from the SPECTRUM observational study indicate a safety profile consistent with prior evaluations.
Research
Study demonstrates accuracy of new platform for comparing AI-based DR screening systems
New testing platform allows for comparison of effectiveness and fairness in commercial AI systems.
Pipeline
FDA grants Orphan Drug designation to BlueRock's RP cell therapy
Marks second designation for OpCT-001; includes tax credits for qualified clinical testing and, if approved, 7 years of U.S. market exclusivity.
Pipeline
BioAge Labs expands into DME clinical program for oral inhibitor asset
Preclinical evidence on NLRP3 inhibitor BGE-102 shows potential for therapeutic retinal exposure, with an initial POC trial to kick off later this year.
Research
Could high HDL levels lead to lower DR risk?
Study emphasizes importance of monitoring HDL levels in patients with diabetic retinopathy.
Research